Clinical trials: insulin glargine
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
- Trial name
- GRADE (NCT01794143)
- Testing
- Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide)
- Where
- 36 sites in United States
- Volunteers
- 7,850 people
- Sponsor
- GRADE Study Group
Type 2 Diabetes
Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus
This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.
- Trial name
- NCT00765817
- Testing
- exenatide
- Where
- 59 sites in United States, Greece and 4 more
- Volunteers
- 261 people
- Sponsor
- AstraZeneca
Type 1 Diabetes
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group".
- Trial name
- STAR3 (NCT00417989)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 30 sites in United States, Canada
- Volunteers
- 485 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30.
- Trial name
- LixiLan-L (NCT02058160)
- Testing
- Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
- Where
- 236 sites in United States, Australia and 16 more
- Volunteers
- 736 people
- Sponsor
- Sanofi
Diabetes
Simplified Insulin Protocol Using Lantus in Elderly
The purpose of this study is to find out if simplifying your diabetes treatment by decreasing number of insulin injections, with the help of a long acting insulin called glargine, can decrease the episodes of low blood glucose.
- Trial name
- SIMPLE (NCT01480843)
- Testing
- Glargine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Joslin Diabetes Center
Diabetes Mellitus, Type 1
baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus
Primary Objective: To evaluate the efficacy of the association Lantus (once-a-day, od) Apidra (thrice-a-day, tid) in terms of change HbA1c from baseline to end of study (week 24), in patients with Type 1 Diabetes Mellitus (T1DM).
- Trial name
- SUBSTITUTE (NCT01204593)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 43 sites in Algeria, Argentina and 7 more
- Volunteers
- 206 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Evaluation of Efficacy and Safety of Insulin Glargine Injected by Needle-free Jet Syringe
Using CGMS to compare the blood sugar improvement and patient sensibility of insulin glargine injected with needle-free jet injector and conventional insulin pen
- Trial name
- NCT04093284
- Testing
- The needle-free jet injector
- Volunteers
- 60 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Type 2 Diabetes Mellitus
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
This will be a randomized, open label, parallel group, multicenter study. There will be two phases in the study. Phase 1 (Baseline to Week 24) will compare the efficacy and safety of regimens of basal insulin intensified with…
- Trial name
- NCT00467649
- Testing
- pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
- Where
- 37 sites in United States
- Volunteers
- 112 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Effect of Rotating Magnetic Therapy on Blood Glucose Spectrum of Type 2 Diabetic Patients With Glargine Therapy
The aim of the study is to assess the effect of Rotating Magnetic Therapy on blood glucose spectrum of type 2 diabetic patients with glargine therapy using flash glucose monitors
- Trial name
- NCT03983187
- Testing
- Rotating Magnetic Therapy
- Volunteers
- 200 people
- Sponsor
- Majianhua
Healthy Subjects
To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy Subjects
The purpose of this study is to compare the pharmacodynamic profile of a single subcutaneous dose of SHR-3167 injection versus insulin glargine U100 in healthy subjects.
- Trial name
- NCT07588906
- Testing
- SHR-3167 injection；glargine insulin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes
A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety
This is a multicenter, randomized, open, parallel group, active-controlled study. The study period is 25 to 26 weeks, including screening period of 1-2 weeks and treatment period of 24 weeks.
- Trial name
- NCT02491528
- Testing
- insulin Aspart injection, insulin Aspart injection (NovoRapid)
- Where
- 2 sites in China
- Volunteers
- 563 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Type2diabetes, Coronary Artery Disease
Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes
The purpose of the trial is to examine whether treatment with dapagliflozin plus insulin as compared with insulin alone (basal-bolus insulin) will result in similar blood glucose control and similar rate of complications in…
- Trial name
- NCT05457933
- Testing
- Dapagliflozin, Glargine
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Medanta, The Medicity, India
Type 2 Diabetes Mellitus
24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
The purpose of the study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to insulin glargine and metformin with or without thiazolidinediones (TZDs), over a period…
- Trial name
- GetGoal-Duo1 (NCT00975286)
- Testing
- Lixisenatide (AVE0010), Insulin glargine, Pen auto-injector
- Where
- 140 sites in United States, Argentina and 24 more
- Volunteers
- 446 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Primary Objective: Percentage of patients achieving Glycosylated Hemoglobin (HbA1c) < 7% with no severe or nocturnal hypoglycemic episodes at 6 months Secondary Objectives: Glycosylated Hemoglobin (HbA1c) change from baseline to…
- Trial name
- AFICIONADO (NCT01127269)
- Testing
- INSULIN GLARGINE
- Where
- 23 sites in Argentina
- Volunteers
- 178 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes
The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine
- Trial name
- NCT00268645
- Testing
- Insulin Glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 534 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus
This trial was conducted in Europe. The aim of this trial was to compare the pharmacodynamic (the effect of the investigated drug on the body) response of insulin degludec (insulin 454) with insulin glargine at steady-state…
- Trial name
- NCT01868529
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Insulin Glargine Combination Therapies in Type II Diabetics
To compare efficacy of combination therapy of insulin glargine plus glimepiride and metformin versus 2 injections insulin monotherapy with premixed insulin NPH 30/70 bid in terms of change of HbA1c (baseline to endpoint) to show…
- Trial name
- LAPTOP (NCT00783744)
- Testing
- Insulin Glargine, Glimepiride, Metformin
- Where
- 10 sites in Austria, Finland and 8 more
- Volunteers
- 375 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
In traditional step-up approach, the patients with poorly-controlled type 2 diabetes are instructed to take up to 4 insulin injections daily or multiple daily injections (MDI) as the most advanced therapy.
- Trial name
- NCT02846233
- Testing
- GLP1 receptor agonist, basal insulin, SGLT2 inhibitor
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Francisco
Type 1 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin
Primary Objective: To compare the glucose control during treatment with a new formulation of insulin glargine and Lantus in adult participants with type 1 diabetes mellitus Secondary Objectives: To compare a new formulation of…
- Trial name
- NCT01658579
- Testing
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanofi
Type 2 Diabetes, Secondary Drug Failure
Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes
Pioglitazone and insulin glargine are equally effective in achieving glycemic control in secondary drug failure of type 2 diabetes but the mechanisms of actions are different.
- Trial name
- NCT00609856
- Testing
- pioglitazone, insulin glargine
- Where
- Sweden
- Volunteers
- 36 people
- Sponsor
- Skane University Hospital